Brooke E Nichols1, Kim C E Sigaloff, Cissy Kityo, Kishor Mandaliya, Raph L Hamers, Silvia Bertagnolio, Michael R Jordan, Charles A B Boucher, Tobias F Rinke de Wit, David A M C van de Vijver. 1. aDepartment of Virology, Erasmus Medical Center, Rotterdam bPharmAccess Foundation cDepartment of Global Health, Academic Medical Centre of the University of Amsterdam, Amsterdam Institute for Global Health and Development (AIGHD), Amsterdam, The Netherlands dJoint Clinical Research Centre (JCRC), Kampala, Uganda eCoast Province General Hospital, International Center for Reproductive Health (ICRH), Mombasa, Kenya fHIV Department, World Health Organization, Geneva, Switzerland gDepartment of Geographic Medicine and Infectious Disease, Tufts University School of Medicine, Boston, Massachusetts, USA.
Abstract
BACKGROUND: Earlier antiretroviral therapy initiation can reduce the incidence of HIV-1. This benefit can be offset by increased transmitted drug resistance (TDR). We compared the preventive benefits of reducing incident infections with the potential TDR increase in East Africa. METHODS: A mathematical model was constructed to represent Kampala, Uganda, and Mombasa, Kenya. We predicted the effect of initiating treatment at different immunological thresholds (<350, <500 CD4 cells/μl) on infections averted and mutation-specific TDR prevalence over 10 years compared to initiating treatment at CD4 cell count below 200 cells/μl. RESULTS: When initiating treatment at CD4 cell count below 350 cells/μl, we predict 18 [interquartile range (IQR) 11-31] and 46 (IQR 30-83) infections averted for each additional case of TDR in Kampala and Mombasa, respectively, and 22 (IQR 17-35) and 32 (IQR 21-57) infections averted when initiating at below 500. TDR is predicted to increase most strongly when initiating treatment at CD4 cell count below 500 cells/μl, from 8.3% (IQR 7.7-9.0%) and 12.3% (IQR 11.7-13.1%) in 2012 to 19.0% (IQR 16.5-21.8%) and 19.2% (IQR 17.1-21.5%) in 10 years in Kampala and Mombasa, respectively. The TDR epidemic at all immunological thresholds was comprised mainly of resistance to non-nucleoside reverse transcriptase inhibitors. When 80-100% of individuals with virological failure are timely switched to second-line therapy, TDR is predicted to decline irrespective of treatment initiation threshold. CONCLUSION: Averted HIV infections due to the expansion of antiretroviral treatment eligibility offset the risk of transmitted drug resistance, as defined by more infections averted than TDR gained. The effectiveness of first-line non-nucleoside reverse transcriptase inhibitor-based therapy can be preserved by improving switching practices to second-line therapy.
BACKGROUND: Earlier antiretroviral therapy initiation can reduce the incidence of HIV-1. This benefit can be offset by increased transmitted drug resistance (TDR). We compared the preventive benefits of reducing incident infections with the potential TDR increase in East Africa. METHODS: A mathematical model was constructed to represent Kampala, Uganda, and Mombasa, Kenya. We predicted the effect of initiating treatment at different immunological thresholds (<350, <500 CD4 cells/μl) on infections averted and mutation-specific TDR prevalence over 10 years compared to initiating treatment at CD4 cell count below 200 cells/μl. RESULTS: When initiating treatment at CD4 cell count below 350 cells/μl, we predict 18 [interquartile range (IQR) 11-31] and 46 (IQR 30-83) infections averted for each additional case of TDR in Kampala and Mombasa, respectively, and 22 (IQR 17-35) and 32 (IQR 21-57) infections averted when initiating at below 500. TDR is predicted to increase most strongly when initiating treatment at CD4 cell count below 500 cells/μl, from 8.3% (IQR 7.7-9.0%) and 12.3% (IQR 11.7-13.1%) in 2012 to 19.0% (IQR 16.5-21.8%) and 19.2% (IQR 17.1-21.5%) in 10 years in Kampala and Mombasa, respectively. The TDR epidemic at all immunological thresholds was comprised mainly of resistance to non-nucleoside reverse transcriptase inhibitors. When 80-100% of individuals with virological failure are timely switched to second-line therapy, TDR is predicted to decline irrespective of treatment initiation threshold. CONCLUSION: Averted HIV infections due to the expansion of antiretroviral treatment eligibility offset the risk of transmitted drug resistance, as defined by more infections averted than TDR gained. The effectiveness of first-line non-nucleoside reverse transcriptase inhibitor-based therapy can be preserved by improving switching practices to second-line therapy.
Authors: Nicholus Mutenda; Alexandra Bukowski; Anne-Marie Nitschke; Tuli Nakanyala; Ndapewa Hamunime; Tadesse Mekonen; Francina Tjituka; Greatjoy Mazibuko; Samson Mwinga; David Mabirizi; Evans Sagwa; Rosalia Indongo; Natalie Dean; Michael R Jordan; Steven Y Hong Journal: PLoS One Date: 2016-12-01 Impact factor: 3.240
Authors: Stéphanie Blaizot; Helena Huerga; Benjamin Riche; Tom Ellman; Amir Shroufi; Jean-François Etard; René Ecochard Journal: BMC Infect Dis Date: 2017-07-26 Impact factor: 3.090
Authors: Andrew N Phillips; John Stover; Valentina Cambiano; Fumiyo Nakagawa; Michael R Jordan; Deenan Pillay; Meg Doherty; Paul Revill; Silvia Bertagnolio Journal: J Infect Dis Date: 2017-05-01 Impact factor: 5.226
Authors: Brooke E Nichols; Kim C E Sigaloff; Cissy Kityo; Raph L Hamers; Rob Baltussen; Silvia Bertagnolio; Michael R Jordan; Timothy B Hallett; Charles A B Boucher; Tobias F Rinke de Wit; David A M C van de Vijver Journal: J Int AIDS Soc Date: 2014-12-05 Impact factor: 5.396
Authors: Brooke E Nichols; Hannelore M Götz; Eric C M van Gorp; Annelies Verbon; Casper Rokx; Charles A B Boucher; David A M C van de Vijver Journal: PLoS One Date: 2015-11-10 Impact factor: 3.240
Authors: Evelyn Lavu; Ellan Kave; Euodia Mosoro; Jessica Markby; Eman Aleksic; Janet Gare; Imogen A Elsum; Gideon Nano; Petronia Kaima; Nick Dala; Anup Gurung; Silvia Bertagnolio; Suzanne M Crowe; Mark Myatt; Anna C Hearps; Michael R Jordan Journal: PLoS One Date: 2017-02-01 Impact factor: 3.240